Search results (666)
« Back to NewsThe latest updates on our research and how it is improving people’s lives.
Common virus may improve skin cancer treatment outcomes, study finds
25 April 2025
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
CRUK funding for research into earlier detection of relapse in people with multiple myeloma
23 April 2025
Dr Karthik Ramasamy and team will assess a new mass spectrometry-based monitoring technique for its ability to predict and identify early disease relapse.
New ultrasound drug delivery system found to be highly effective against bacterial biofilms
22 April 2025
Researchers at the University of Oxford have developed a new drug delivery system using ultrasound-activated nanoparticles to break through and destroy bacterial biofilms. This offers a promising solution that could address the global crisis of chronic antibiotic-resistant infections affecting hundreds of millions of people worldwide.
New research highlights colorectal cancer trends and survival rates
16 April 2025
A recent study published in the American Journal of Gastroenterology investigates the incidence and survival rates of colorectal cancer (CRC) in the UK. The research offers healthcare decision-makers crucial insights for planning, management and screening for colorectal cancer.
New CONSORT reporting guidelines published today in five medical journals
15 April 2025
The CONSORT 2025 statement, an updated guideline for reporting randomised trials is being simultaneously published in The BMJ, JAMA, The Lancet, Nature Medicine, and PLOS Medicine.
NDORMS leads study on burosumab for adults with rare inherited disorder
10 April 2025
NDORMS researchers have been awarded funding to explore the long-term effects of burosumab in adults with X-linked hypophosphataemia (XLH).
Blood cancer patients should continue treatment at time of COVID-19 vaccination, OCTRU study shows
9 April 2025
Evidence shows for patients with a type of leukaemia, pausing BTKi therapy for COVID-19 vaccination does not improve antibody responses to the vaccine
Global study supports the immunity debt hypothesis for flu after Covid restrictions
7 April 2025
A new NDORMS study supports the hypothesis of immunity debt showing increases of influenza rates one year after global relaxation of COVID-19 restrictions. It highlights the need for proactive preparations in future pandemic response strategies.
PROBAST+AI guidelines updated to improve AI quality assessment
2 April 2025
The PROBAST+AI guidelines have been updated to provide clearer, more comprehensive standards for evaluating artificial intelligence (AI) models in healthcare research. Originally introduced to assess the risk of bias and the robustness of prediction models, they have been revised to address the growing importance of AI in healthcare decision-making.
New research uncovers pathways to prevent premature cell death
28 March 2025
New research from the Kennedy Institute has revealed how two important proteins, TBK1 and IKKe, play a crucial role in preventing premature cell death, which can lead to serious inflammation in the body. The findings are particularly relevant for people with a mutation in the TBK1 gene who often develop multiorgan inflammation caused by excessive cell death even in the absence of any infection.
Decoding the interplay between genes and mechanics in tissues at single-cell resolution
17 March 2025
Researchers at the Kennedy Institute have developed a new computational framework that allows simultaneous analysis of gene expression and mechanical forces within cells and tissues, uncovering insights into how the interplay between transcriptional and mechanical signals guides processes such as cell fate decisions or the formation of spatially distinct tissue compartments.
Innovative bead design will enhance single-cell transcriptomics accuracy
13 March 2025
Researchers at NDORMS have made an important advancement in the field of single-cell transcriptomics by developing a novel bead design that reduces errors in DNA synthesis and improves the reliability of gene expression measurements.
New guidelines to build trusted AI in healthcare research
5 March 2025
A new set of guidelines have been launched to create trustworthy AI systems in healthcare. The first of its kind, the FUTURE-AI guideline provides recommendations covering the entire lifecycle of medical AI, from design, development and validation to regulation, deployment, and monitoring.
NDORMS receives funding to tackle the global burden of musculoskeletal injuries
27 February 2025
A grant from the National Institute for Health and Care Research (NIHR) is funding a study to improve healthcare treatment and care for patients with broken bones in three Sub-Saharan Africa countries.
New partnership with Johnson & Johnson Innovative Medicine announced
13 February 2025
The Translational Pharmacology Group, led by James Fullerton at NDORMS, has announced a significant new partnership with Johnson & Johnson Innovative Medicine to leverage their human experimental medicine platform.
Pancreatic cancer immune map provides clues for precision treatment targeting
7 February 2025
Study shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
New theory explains reporting of suspected adverse drug reactions to biological therapies used in rheumatology care
4 February 2025
A recent study introduces "Pragmatic Situational Practice Outcomes," shedding light on the complexities affecting how patients and healthcare professionals report suspected ADRs related to biologic medications.
Stephanie Dakin awarded a Versus Arthritis Bridging Fellowship
29 January 2025
Professor Stephanie Dakin has been awarded a Versus Arthritis Bridging Fellowship to advance the work of her Versus Arthritis sponsored Career Development Fellowship investigating frozen shoulder.
An interview with Audrey Gerard
21 January 2025
Audrey Gerard, an Associate Professor of Immune Cell Dynamics and Principal Investigator at the Kennedy Institute of Rheumatology, is working to understand how the immune response interacts with and shapes tumours.
Professor Michael Dustin named AAI Distinguished Fellow
20 January 2025
The American Association of Immunologists (AAI) has recognised the outstanding work of the Kennedy Institute’s Professor of Molecular Immunology Michael Dustin by naming him a Distinguished Fellow of AAI.